Case Study: Sarah, a vibrant 52-year-old woman, received the life-altering news – HR+ breast cancer. Like many diagnosed with this type, she embarked on the standard treatment path of aromatase inhibitors, hoping to starve the cancer of its estrogen fuel. Initially, the tumor shrank, offering a glimmer of hope. However, after two years, a disheartening … Continue reading Unmasking the Estrone Tango in Sarah’s HR+ Breast Cancer